Hospital
Okanogan County Public Hospital Dist No 4
Okanogan County Public Hospital Dist No 4 was paid $16.00M by Medicaid between Jan 2018 and Nov 2024, across 115 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoOKANOGAN COUNTY PUBLIC HOSPITAL DIST NO 4
TONASKET, WA 98855
TONASKET, WA 98855
33aNPI1164580700assigned 12/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.00M
24GClaims171,492
24DCodes billed115
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#30 of 49
Median peer was paid$20.06M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,938 | $1.47M | |
| 2019 | 22,969 | $1.78M | |
| 2020 | 22,813 | $2.09M | |
| 2021 | 28,644 | $2.37M | |
| 2022 | 29,225 | $3.05M | |
| 2023 | 27,907 | $2.75M | |
| 2024incomplete | 20,996 | $2.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 7,569 | 5,874 | $3.27M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 8,265 | 6,958 | $2.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 3,969 | 2,941 | $2.37M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.1% | 10,502 | 3,634 | $1.30M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 2,302 | 1,604 | $476K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.7% | 5,070 | 1,823 | $432K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 1,953 | 1,736 | $385K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 847 | 571 | $383K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 1,378 | 829 | $314K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 3,015 | 2,062 | $285K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 2,984 | 2,262 | $258K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.6% | 1,677 | 787 | $250K |
103 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 9,390 | $225K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 2,448 | $210K |
| 80053 | Comprehensive metabolic panel | 1.3% | 8,534 | $210K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 2,507 | $199K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 3,247 | $193K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 4,041 | $181K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 3,533 | $171K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 1,774 | $163K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,708 | $140K |
| G0378 | Hospital observation service, per hour | <1% | 278 | $136K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,010 | $111K |
| 83605 | <1% | 3,280 | $90K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 670 | $83K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,640 | $83K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,353 | $80K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,005 | $76K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,906 | $76K |
| 84484 | <1% | 2,839 | $72K | |
| 87631 | <1% | 385 | $67K | |
| 83880 | <1% | 802 | $54K | |
| 83690 | <1% | 2,493 | $53K | |
| 86140 | <1% | 3,220 | $52K | |
| 81001 | <1% | 5,398 | $50K | |
| 97162 | <1% | 380 | $49K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,602 | $45K |
| 97130 | <1% | 187 | $42K | |
| 97161 | <1% | 419 | $40K | |
| 97602 | <1% | 292 | $38K | |
| 84703 | <1% | 1,025 | $34K | |
| 83735 | <1% | 1,718 | $32K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 190 | $32K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 254 | $32K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 113 | $28K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,871 | $28K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 627 | $27K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,650 | $24K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 136 | $24K |
| 85379 | <1% | 909 | $23K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 266 | $23K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,189 | $20K |
| A9270 | Non-covered item or service | <1% | 15,453 | $18K |
| 73030 | <1% | 212 | $17K | |
| 85610 | <1% | 1,680 | $17K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,434 | $17K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 298 | $15K |
| 97129 | <1% | 208 | $15K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 83 | $14K |
| 0002A | <1% | 392 | $13K | |
| 73610 | <1% | 128 | $13K | |
| 0001A | <1% | 437 | $13K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 37 | $12K |
| 87040 | <1% | 567 | $12K | |
| 87088 | <1% | 626 | $11K | |
| 85730 | <1% | 793 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 172 | $10K |
| 73562 | <1% | 118 | $9K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 545 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 295 | $8K |
| 36592 | <1% | 138 | $8K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 91 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 471 | $7K |
| J3490 | Unclassified drugs | <1% | 312 | $7K |
| 80061 | Lipid panel | <1% | 137 | $6K |
| 76801 | <1% | 16 | $6K | |
| 97163 | <1% | 28 | $5K | |
| 87184 | <1% | 288 | $5K | |
| 87077 | <1% | 226 | $5K | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 14 | $5K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 16 | $5K |
| 82077 | <1% | 105 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 89 | $4K |
| 87081 | <1% | 133 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 121 | $4K |
| 73630 | <1% | 30 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 234 | $4K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 35 | $3K |
| 73130 | <1% | 35 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 84 | $2K |
| 97010 | <1% | 316 | $2K | |
| 84479 | <1% | 27 | $2K | |
| 87070 | <1% | 45 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 32 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 77 | $1K |
| 84145 | <1% | 13 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 600 | $1K |
| 90715 | <1% | 12 | $1K | |
| 85651 | <1% | 72 | $968.17 | |
| 96376 | <1% | 38 | $833.98 | |
| 87807 | <1% | 13 | $746.10 | |
| 36000 | <1% | 16 | $705.64 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 73 | $663.26 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 29 | $648.17 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 12 | $609.89 |
| 82948 | <1% | 89 | $569.06 | |
| J2704 | Injection, propofol, 10 mg | <1% | 39 | $479.06 |
| 0004A | <1% | 13 | $440.00 | |
| 97035 | <1% | 29 | $431.11 | |
| 94770 | <1% | 14 | $418.50 | |
| 84436 | <1% | 12 | $378.96 | |
| 85027 | <1% | 16 | $351.88 | |
| 82803 | <1% | 14 | $132.78 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,053 | $2.40 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 937 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCREYNOLDS, JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Okanogan County Public Hospital Dist No 4 | Tonasket, WA | $664K |
| Okanogan County Public Hospital Dist No 4 | Tonasket, WA | $296K |
| Mcreynolds Anesthesia, PA | Columbus, MS | $84K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.